Index Entries

Einav G. Levin, Yaniv Lustig, Carmit Cohen, Ronen Fluss, Victoria Indenbaum, Sharon Amit, Ram Doolman, Keren Asraf, Ella Mendelson, Arnona Ziv, Carmit Rubin, Laurence Freedman, Yitshak Kreiss, and Gili Regev-Yochay
October 6, 2021
New England Journal of Medicine (NEJM)
Sheba Medical Center (Israel)

Methods: We conducted a 6-month longitudinal prospective study involving vaccinated health care workers who were tested monthly for the presence of anti-spike IgG and neutralizing antibodies. Linear mixed models were used to assess the dynamics of antibody levels and to determine predictors of antibody levels at 6 months.

Results: The study included 4868 participants, with 3808 being included in the linear mixed-model analyses. The level of IgG antibodies decreased at a consistent rate, whereas the neutralizing antibody level decreased rapidly for the first 3 months with a relatively slow decrease thereafter…

Conclusions: Six months after receipt of the second dose of the BNT162b2 [Pfizer] vaccine, humoral [immune] response was substantially decreased, especially among men, among persons 65 years of age or older, and among persons with immunosuppression.”

document
breakthrough cases,COVID-19,vaccines